Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon May 13, 2021 9:54am
148 Views
Post# 33190740

RE:RE:Halt ... just a shuffle

RE:RE:Halt ... just a shuffle
PitchinPennies wrote: Reading between the lines, this suggests JRG might be recognizing his own limitations, which is completely in conflict with JRG's personal brand and life-story. Samira's a great person, but, let's be honest, she's a skilled factotum, not a rainmaker. Mark Beaudet was the person who could take Goodman's ideas and turn them into reality, back at Paladin. I'd be buying Kinght if Mark returned to the scene of the crime, but this news just makes me wonder all the more about exactly what's going on, both with Jonathan and his blurry vision of Paladin Act II. 


We know Mark wasn't interested in coming back to pharma "full-time" and certainly Samira was being groomed for this position.

She moved from President ... to President/CFO ... then President/COO and now President/CEO.

It sounds like Goodman continues to do what he's been doing to guide the business - with less involvement in day-to-day.  That's what I'm seeing.
<< Previous
Bullboard Posts
Next >>